Ewing's tumour is the second most frequent primary bone tumour in children. Despite an incrase in the overall survival of patients with Ewing's tumour owing to the use of systemic chemotherapy, the overall long-term survival is still limited to 50-60% of patients in recent series (Horowitz et al., 1993) . A major prognostic factor is the presence or absence of disseminated disease. The most frequent metastatic sites are lung, bone and bone marrow, which are attained through an haematogenous route (Horowitz et al., 1993) . Presently, the detection of metastasis relies on imaging evaluation of lung and bone and on cytological and histological analysis of bone marrow. However, in the absence of specific markers for Ewing cells, only an important contamination of bone marrow can be detected suggesting that the number of patients with metastatic tumours at diagnosis might be underestimated. Thus, sensitive detection of tumour cells in peripheral blood or bone marrow may be important for staging and follow-up.
The recent cloning of the specific chromosome translocation t(1l;22Xq24;ql2) which characterises Ewing's tumours has provided a new, promising marker (Aurias et al., 1983; Turc-Carel et al., 1983; Delattre et al., 1992; Zucman et al., 1992) . Indeed, this chromosome alteration results in a fusion gene by juxtaposing the EWS gene on chromosome 22 and the FLI-I gene on chromosome 11 (Delattre et al., 1992) . In a subset of tumours, as a result of a rearrangement between chromosome 22 and 21, the EWS gene is fused with another member of the Ets family of transcription factors highly homologous to FLI-J, the ERG gene (Zucman et al., 1993a; Sorensen et al., 1994) . These fusion genes encode fusion transcripts which can be detected by the specific amplification of the junctional region using the reverse transcriptasepolymerase chain reaction (RT-PCR) technique. Analysis of large series of small round cell tumours in children has shown that at least 95% of Ewing tumours are associated with either an EWS/FLI-I or an EWS/ERG fusion transcript which, therefore, constitutes a specific marker for this group of tumours (Delattre et al., 1994; Giovannini et al., 1994) .
Tumour-specific gene alterations resulting from chromosomal translocations are frequent in leukaemias and lymphomas (Cline, 1994) . Their identification, which relies on highly sensitive PCR-based methods, is now widely used to detect small numbers of tumour cells in blood, bone marrow or stem cell harvests from patients.
Solid tumours demonstrating such specific markers are rarer. However, they constitute a model system for the study of the metastatic process and for the appreciation of the clinical applications linked to the use of such highly sensitive techniques in the detection of malignant cells in solid tumours.
In this study, we describe a method, based on the nested PCR amplificiation of the EWS/FLI-I or ERG fusion transcripts, which enables the detection of small numbers of Ewing cells in biological samples. This technique was applied to detect the EWS/FLI-I or ERG fusion transcripts from mononuclear cells isolated from blood, bone marrow and peripheral stem cell harvests in patients suffering from Ewing's tumour.
Matedak and mthods

Patients
The study population consisted of 36 patients treated for Ewing's tumour from 1992 to 1993. Sixteen patients were analysed at diagnosis, before treatment. Eighteen patients were studied after induction therapy, at the time of bone marrow or peripheral stem cell harvests. Two patients were analysed at the time of relapse; both had lung metastasis. Finally, three patients could be studied both at diagnosis and at the time of stem cell harvest. (Naito et al., 1991; Mattano et al., 1992; Burchill et al., 1994) . In the same way, tyrosinase, keratn 19 and prostate-specific antigen have been used to detect tumour cells in patients with melanoma, breast car--cinoma and prostate canc respectively (Smith et al., 1991; Moreno et al., 1992; Datta et al., 1994 This method was evaluated on biological samples from patients. At diagosis, one-third of the patients presented with involvement of blood, bone marrow or both. None of these patients had detectable metastases as evaluated by chest CT scan and cytohistological examination of the bone marrow. This demonstrated that regional disease can be accompanied by circulating tumour cells or occult bone marrow metastasis. The impact of these findings on evolution of the disease will necessitate long-term follow-up of these and other patients.
As for other solid tumours, myeloablative therapy with stem cell grafting is now increasingly used for the treatment of Ewing's tumours, particularly in high-risk groups (Horowitz et al., 1993) . The recent demonstration that, in neuroblastoma, malignant cells present in the autologous bone marrow contribute to relapse (Hill et al., 1994) suggests that an identical phenomenon could occur in Ewing's tumour and emphasises the need to test stem cell harvests for tumour cells before grafting. In Ewing's ,Itumour, the method described here now enables evaluationWthe prognostic impications of the psce of tumour cells in stem cell harvests. It can be anticipated that a potentially important application of the method described here will be the regular followup of blood from patients treated for Ewing's tumour. A progressive increase in the number of circulating tumour cells might be indicative of a relapse. We are currently developing a competition assay which should enable precise determination of the number of tumour cells present in the sample.
Finally, the increasing number of tumour-specific genetic alterations described in solid tumours raises the possibility that the approach described here for the Ewing's family of tumours might be applied for other tumours characterised by specific fusion transcripts (Crozat et al., 1993; Galili et al., 1993; Rabbits et al., 1993; Zucman et al., 1993b; Clark et al., 1994; Ladanyi and Gerald 1994 
